A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Idh1 And Idh2 Mutant Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Subjects must be diagnosed with a glioma, cholangiocarcinoma or other solid malignant tumor that has progressed despite standard therapy, or for which no effective standard therapy exists, with biopsy-confirmed evidence of an IDH1 or IDH2 mutation associated with neomorphic activity of the encoded proteins. 2) Patients must have IDH1 or IDH2 mutation which must be detected in a clinical accredited laboratory using an FDA-approved molecular test or a validated DNA-based assay conducted in a CLIA-certified laboratory. 3) Patients must be willing to undergo extra blood sampling for correlative studies. 4) Subjects with extracranial disease must have evaluable disease by RECIST v1.1.

You may not be eligible for this study if the following are true:

  • 1) Participation in another clinical study with an investigational product during the last 30 days or five half-lives of the drug (whichever is less) prior to the initiation of study treatment (6 weeks for nitrosoureas or mitomycin C). 2) Any previous treatment with PARP inhibitor, including olaparib.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.